Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
O00287
UPID:
RFXAP_HUMAN
Alternative names:
RFX DNA-binding complex 36 kDa subunit
Alternative UPACC:
O00287; B2R9T8; Q5VZM6; Q8TC40
Background:
The Regulatory factor X-associated protein, also known as RFX DNA-binding complex 36 kDa subunit, plays a crucial role in the immune system. It is a key component of the RFX complex, which is essential for the binding to the X-box of MHC II promoters, a process vital for the proper expression of MHC II genes.
Therapeutic significance:
Linked to Bare lymphocyte syndrome 2, a severe immunodeficiency disease, this protein's dysfunction leads to a significant decrease in MHC II expression, resulting in a compromised immune response. Understanding the role of Regulatory factor X-associated protein could open doors to potential therapeutic strategies for enhancing immune function.